<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03902444</url>
  </required_header>
  <id_info>
    <org_study_id>ASSISTENT</org_study_id>
    <nct_id>NCT03902444</nct_id>
  </id_info>
  <brief_title>AcandiS Stenting of Intracranial STENosis - regisTry</brief_title>
  <acronym>ASSISTENT</acronym>
  <official_title>AcandiS Stenting of Intracranial STENosis - regisTry</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Acandis GmbH</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Acandis GmbH</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
  </oversight_info>
  <brief_summary>
    <textblock>
      ASSISTENT is designed to collect comprehensive information on technical and clinical safety
      of the use of Credo® stent together with the NeuroSpeed® PTA balloon catheter in clinical
      practice in an open registry.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      ASSISTENT is subdivided into two components. The first part only requires recording of data
      acquired in routine clinical practice during the treatment of patients with intracranial
      stenosis with the self-expandable Credo® stent until discharge. This comprises demographic
      data, data concerning the qualifying clinical event, limited data on medical history and
      medication, information about the intervention including technical success and periprocedural
      complications or events, and information about events and clinical status during the
      in-hospital treatment until hospital discharge.

      The second part of the registry consists of a follow-up visit 30 days after the
      interventional procedure which will be conducted outside of clinical practice.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 2016</start_date>
  <completion_date type="Anticipated">April 2020</completion_date>
  <primary_completion_date type="Anticipated">March 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of Technical Success</measure>
    <time_frame>During interventional procedure</time_frame>
    <description>• Technical Success</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Patients with Periprocedural Vascular Events</measure>
    <time_frame>Periprocedural, until 30 days after the interventional procedure</time_frame>
    <description>Intracranial haemorrhage (symptomatic / asymptomatic)
Death
TIA in the region of the target vessel
Non-disabling ischemic stroke (MRS 0-2) in the region of the target vessel
Disabling ischemic stroke (MRS 3-6) in the region of the target vessel
TIA outside the region of the target vessel
Non-disabling ischemic stroke (MRS 0-2) outside the region of the target vessel
Disabling ischemic stroke (MRS 3-6) outside the region of the target vessel</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Patients with Cerebrovascular events</measure>
    <time_frame>At hospital discharge - befor the patient leaves the hospital after the intervention; up to 2 weeks, whichever came first</time_frame>
    <description>Intracranial haemorrhage (symptomatic / asymptomatic)
Death
TIA in the region of the target vessel
Non-disabling ischemic stroke (MRS 0-2) in the region of the target vessel
Disabling ischemic stroke (MRS 3-6) in the region of the target vessel
TIA outside the region of the target vessel
Non-disabling ischemic stroke (MRS 0-2) outside the region of the target vessel
Disabling ischemic stroke (MRS 3-6) outside the region of the target vessel</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Patients with Cerebrovascular Events</measure>
    <time_frame>30 days after the interventional procedure</time_frame>
    <description>Intracranial haemorrhage (symptomatic / asymptomatic)
Death
TIA
Non-disabling ischemic stroke (MRS 0-2)
Disabling ischemic stroke (MRS 3-6)
Interventional re-treatment of the target vessel</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Patients with Dissection of the target vessel</measure>
    <time_frame>During interventional procedure</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients with Occlusion of the target vessel</measure>
    <time_frame>30 days after the interventional procedure</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients with Myocardial infarction</measure>
    <time_frame>30 days after the interventional procedure</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients with Severe extracranial hemorrhage (requiring surgical treatment or transfusion)</measure>
    <time_frame>30 days after the interventional procedure</time_frame>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Intracranial Stenosis</condition>
  <arm_group>
    <arm_group_label>Credo® Stent and NeuroSpeed® PTA balloon catheter</arm_group_label>
    <description>Patients treated with Credo® Stent and NeuroSpeed® PTA balloon catheter in the clinical routine</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Credo® Stent, NeuroSpeed® PTA balloon catheter</intervention_name>
    <description>a self-expanding stent is used together with a PTA balloon catheter</description>
    <arm_group_label>Credo® Stent and NeuroSpeed® PTA balloon catheter</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        All patients over 18 with symptomatic intracranial artery stenosis treated with the
        self-expandable Credo® stent in the participating sites in clinical practice.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

        - Treatment with Credo® for symptomatic atherosclerotic intracranial artery stenosis (see
        product IFU)

        Exclusion Criteria:

          -  There are no specific exclusion criteria (see product IFU)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Götz Thomalla, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Unversity Medical Center Hamburg-Eppendorf</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Acandis GmbH</last_name>
    <phone>+49 723 1155 00</phone>
    <email>info@acandis.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Universitätsklinikum Knappschaftskrankenhaus Bochum</name>
      <address>
        <city>Bochum</city>
        <zip>44892</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Priv. Doz. Dr. med. Sebastian Fischer</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Alfried Krupp Krankenhaus Essen, Klinik für Neuroradiologie</name>
      <address>
        <city>Essen</city>
        <zip>45131</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rene Chapot, Prof.</last_name>
    </contact>
    <investigator>
      <last_name>Rene Chapot, Prof</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Hamburg-Eppendorf</name>
      <address>
        <city>Hamburg</city>
        <zip>20246</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Götz Thomalla, MD</last_name>
    </contact>
    <investigator>
      <last_name>Jan Buhk</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Asklepios Klinik Altona, Fachbereich Neuroradiologie</name>
      <address>
        <city>Hamburg</city>
        <zip>22769</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bernd Eckert, Prof</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Heidelberg Abteilung für Neuroradiologie</name>
      <address>
        <city>Heidelberg</city>
        <zip>69120</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Markus Möhlenbruch, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Homburg</name>
      <address>
        <city>Homburg</city>
        <zip>66424</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wolfgang Reith, Prof.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Klinikum Ingolstadt</name>
      <address>
        <city>Ingolstadt</city>
        <zip>85049</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Dr. Hendrik Janssen</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Uniklinik Köln</name>
      <address>
        <city>Köln</city>
        <zip>50924</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Christoph Kabbasch, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kliniken Maria Hilf GmbH Mönchengladbach, Klinik für Diagnostische und Interventionelle Radiologie und Neuroradiologie</name>
      <address>
        <city>Mönchengladbach</city>
        <zip>41063</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Prof. Ringelstein</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Evangelisches Krankenhaus Oldenburg; Medizinischer Campus Universität Oldenburg</name>
      <address>
        <city>Oldenburg</city>
        <zip>26122</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christian Mathys, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Klinikum Osnabrück, Klinik für Neurologie</name>
      <address>
        <city>Osnabrück</city>
        <zip>49076</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lars Krause, MD</last_name>
    </contact>
    <investigator>
      <last_name>Stephan Lowens, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>St. Lukas Klinik GmbH, radprax MVZ GmbH Solingen</name>
      <address>
        <city>Solingen</city>
        <zip>42697</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hannes Nordmeyer, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>March 2019</verification_date>
  <study_first_submitted>March 27, 2019</study_first_submitted>
  <study_first_submitted_qc>April 2, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">April 4, 2019</study_first_posted>
  <last_update_submitted>October 22, 2019</last_update_submitted>
  <last_update_submitted_qc>October 22, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 23, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Constriction, Pathologic</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

